Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7506013 | Drug and Alcohol Dependence | 2014 | 4 Pages |
Abstract
Lifetime synthetic cannabinoid use was relatively common in SUD patients and many of those who used it reported doing so because they believed it would not result in a positive drug test. Further research is needed to characterize the extent of synthetic cannabinoid use among SUD treatment samples, and to establish understanding of the longitudinal trajectories of synthetic cannabinoid use in combination with other substance use, psychiatric distress, and treatment outcomes.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Erin E. Bonar, Lisham Ashrafioun, Mark A. Ilgen,